Impact of comorbidities on patients with COVID-19: A large retrospective study in Zhejiang, China
Open Access
- 1 November 2020
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 92 (11), 2821-2829
- https://doi.org/10.1002/jmv.26183
Abstract
Coronavirus disease 2019 (COVID-19) has become a serious public health problem worldwide. Here, we stratified COVID-19 patients based on their comorbidities to assess their risk of serious adverse outcomes. We collected 856 hospitalized cases diagnosed with COVID-19 from 17 January to 7 February 2020, in Zhejiang Province, and analyzed their comorbidities and composite endpoint (including admission to intensive care unit owing to disease progression, shock, invasive ventilation, and death) to determine the relationship between comorbidities and adverse outcomes. The median age of patients was 46 (36-56) years; 439 (51.3%) were men, 242 (28.3%) had comorbidities, and 152 (17.8%) had two or more comorbidities. The most common comorbidity was hypertension (142 [16.6%]), followed by diabetes (64 [7.5%]). Of the 856 patients, there are 154 (18.0%) severe cases. Thirty-two (3.7%) reached composite endpoints, of which 22 (9.1%) were from the comorbidity group and 10 (1.6%) from the non-comorbidity group (P < .001). After adjusting for age and gender status, the risk of reaching the composite endpoint was higher in the group with comorbidity than in that without comorbidity (hazard ratio [HR] 3.04, 95% confidence interval [CI]: 1.40-6.60). HR values for patients with one, two, and three or more comorbidities were 1.61 (95% CI: 0.44-5.91), 3.44 (95% CI: 1.31-9.08), and 6.90 (95% CI: 2.69-17.69), respectively. COVID-19 patients with comorbidities had worse clinical outcomes as compared with those without any comorbidity. The higher the number of comorbidities, the greater was the risk of serious adverse outcomes.This publication has 31 references indexed in Scilit:
- The risk factors associated with MERS-CoV patient fatality: A global surveyDiagnostic Microbiology and Infectious Disease, 2020
- Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective studyEpidemiology and Infection, 2018
- Epidemiological, clinical and viral characteristics of fatal cases of human avian influenza A (H7N9) virus in Zhejiang Province, ChinaJournal of Infection, 2013
- Impact of Age and Comorbidity on Cause and Outcome in Community-Acquired PneumoniaSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2013
- Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive studyThe Lancet Infectious Diseases, 2013
- Weakened immunity in aged hosts with comorbidities as a risk factor for the emergence of influenza A H7N9 mutants.Journal of Infection in Developing Countries, 2013
- Mortality of 2009 pandemic influenza A(H1N1) in GermanyEurosurveillance, 2010
- Hospitalized Patients with 2009 H1N1 Influenza in the United States, April–June 2009The New England Journal of Medicine, 2009
- Clinical Manifestations, Laboratory Findings, and Treatment Outcomes of SARS PatientsEmerging Infectious Diseases, 2004
- Transmission Dynamics of the Etiological Agent of SARS in Hong Kong: Impact of Public Health InterventionsScience, 2003